Bayer to Build Cell Therapy Pipeline with BlueRock Therapeutics Acquisition
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 8 (Table of Contents)
Published: 16 Aug-2019
DOI: 10.3833/pdr.v2019.i8.2451 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Less than three years after forming BlueRock Therapeutics with Versant Ventures, Bayer has now moved to fully acquire BlueRock which focuses on engineered cell therapies in the areas of neurology, cardiology and immunology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS